Reordering the pecking order: management describes the company winning on a stage where it used to be too small to play
The model's full reasoning — Q4 2022 call → NOThe question asks whether management describes the company as now competing and winning at a level of the market that used to be above it — that is, a change in tier, already real, and early. Let me scan the transcript for relevant statements. Chad Robins: "In MRD, clonoSEQ clinical volumes grew 51% versus fiscal year 2021 supported by our fully trained sales team, which we nearly doubled during the year. In addition, we launched clonoSEQ and DLBCL and signed an agreement with Epic for EMR integration." Nitin Sood: "I think first of all, I just want to remind everyone that our current penetration is about 5%. So there's a lot of room for us to grow." Chad Robins: "We also mentioned kind of Epic integration in the back half of the year, I think that really being able to go right into your EHR and order directly from there should especially on accounts that are already ordering clonoSEQ, we think that should accelerate usage." Nitin Sood: "And in one particular account, after engaging with them over several months, they have sort of standardized their clinical workflows on clonoSEQ upon arrival of every patient that's diagnosed. For example, with CLL. And we expect more of these to happen in 2023 and be a key contributor to growth." Chad Robins: "And then, I'll make an overall comment that, I think I'm seeing, and I don't know, we can agree on this, but MRD in general is becoming a much more accepted by healthcare providers. It took a long time to get here. And I actually think even a lot of the noise around MRD and solid tumors, and just kind of a nomenclature and understanding kind of what the assay is, and no one wants to be first, but no one else wants to be last. And we're kind of hitting that starting to, I would say, starting to hit that point where it's become kind of more common practice." Hmm. The question is about whether the company has moved up a tier in its market. Let me look for specific language about competing against larger players, winning business that previously went to others, or being admitted to a roster.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
PRIM · Q2 2018 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing exactly this tier shift in the T&D segment: after the Willbros acquisition, the group “has been able to sign new awards with customers that have been hesitant because of previous concerns about their financial viability” and has received work from “some of the largest electrical utilities in the country.” David King notes that the work “outpaces anything he has seen in his 40-plus years,” and Pete Moerbeek adds that the one-year MSA revenue alone is now $1.1 million. Management presents these wins as a direct result of Primoris’s financial strength and parent-company backing, which previously excluded the T&D business from the largest accounts. The commentary frames the development as newly enabled and still early (only one month of T&D performance), satisfying all three required elements: a clear change in competitive tier, real business already won, and contribution still incremental relative to the company’s prior scale.
SANG · Q2 2024 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing a shift to competing at a higher tier with sophisticated mid-market clients through bundled offerings, illustrated by a recent win with a statewide park department that larger vendors couldn't serve affordably. They explicitly note this represents a change in tier ("the type of client the bundled capabilities of Sangoma can reach ... Sangoma is well positioned to play in both the small market and more sophisticated mid-market") and that it has already produced real results ("this recent win"), while conveying it is early ("there'll be a lag before it delivers material results.
WD · Q2 2022 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management explicitly describing a tier shift: from competing "predominantly with the likes of JPMorgan and Wells Fargo" to "going head-to-head with CBRE and JLL," enabled by technology investments that now allow them to "successfully compete against these much larger firms.